Aquestive Therapeutics Files 8-K with Financials

Ticker: AQST · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1398733

Aquestive Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAquestive Therapeutics, Inc. (AQST)
Form Type8-K
Filed DateSep 27, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-statements, disclosure

Related Tickers: AQST

TL;DR

AQST filed an 8-K on 9/27 with financials. Check it out.

AI Summary

Aquestive Therapeutics, Inc. filed an 8-K on September 27, 2024, reporting on various events. The filing includes financial statements and exhibits, and is categorized under Regulation FD Disclosure and Other Events. The company, formerly known as MonoSol Rx, Inc., is incorporated in Delaware and headquartered in Warren, NJ.

Why It Matters

This 8-K filing provides updated financial information and disclosures for Aquestive Therapeutics, Inc., which is important for investors to assess the company's current financial health and operational status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report containing financial statements and general disclosures, not indicating any immediate or significant negative events.

Key Players & Entities

  • Aquestive Therapeutics, Inc. (company) — Registrant
  • MonoSol Rx, Inc. (company) — Former company name
  • September 27, 2024 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation
  • Warren, NJ (location) — Principal executive offices

FAQ

What is the primary purpose of this 8-K filing for Aquestive Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report on various events, including financial statements and exhibits, under Regulation FD Disclosure and Other Events.

When was this 8-K report filed by Aquestive Therapeutics, Inc.?

This 8-K report was filed on September 27, 2024.

What was Aquestive Therapeutics, Inc. formerly known as?

Aquestive Therapeutics, Inc. was formerly known as MonoSol Rx, Inc.

In which state is Aquestive Therapeutics, Inc. incorporated?

Aquestive Therapeutics, Inc. is incorporated in Delaware.

Where are Aquestive Therapeutics, Inc.'s principal executive offices located?

Aquestive Therapeutics, Inc.'s principal executive offices are located at 30 Technology Drive, Warren, NJ 07059.

Filing Stats: 785 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-09-27 08:46:44

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I

Filing Documents

01

Item 7.01 Regulation FD Disclosure. Aquestive Therapeutics, Inc. (the "Company") is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation and accompanying oral commentary, to be given at a virtual investor day event (the "Investor Day Event") and other meetings with institutional investors, analysts and others. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K or a later Company filing or by other means. A copy of the Company's investor presentation at the Investor Day Event is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The investor presentation and accompanying webcast are available on the Events & Presentations page in the Investors section of the Company's website located at www.aquestive.com, although the Company reserves the right to discontinue that availability at any time. A copy of the Company's current corporate presentation given to investors, analysts and others is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The Company's corporate presentation is available on the Events & Presentations page in the Investors section of the Company's website located at www.aquestive.com, although the Company reserves the right to discontinue that availability at any time. The information in this Item 7.01 (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of, Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

01

Item 8.01 Other Events. On September 27, 2024, the Company issued a press release providing an update of its Adrenaverse epinephrine prodrug platform, including the development of its product candidates Anaphylm (epineprhine) Sublingual Film and AQST-108 (epinephrine) Topical Gel, to be provided at the Investor Day Event being hosted by the Company. A copy of the Company's press release is attached hereto as Exhibit 99.3 and incorporated into this Item 8.01 by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Aquestive Therapeutics, Inc. Investor Presentation dated September 27, 2024 99.2 Aquestive Therapeutics, Inc. Corporate Presentation dated September 27, 2024 99.3 Press Release of Investor Day, dated September 27, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 27, 2024 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.